Q3 FY2026 · ended Sep 30, 2026 · Revenue $360.98M, +36.1% YoY · Filed Nov 5, 2026
Guardant Health, Inc. (GH) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $361.0 million and a net loss of $124.4 million. Free cash flow was -$37.2 million. As of Sep 30, 2026 it held $1.0 billion in cash and investments and $1.7 billion in total debt.
Revenue
$360.98M
+36.1% vs year-ago quarter
Net income
$-124.36M
-34.1% vs year-ago quarter
Operating cash flow
$-23.71M
+33.1% vs year-ago quarter
Free cash flow
$-37.19M
+18.7% vs year-ago quarter
EPS
$-0.93
-25.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
135.29M
+7.3% vs year-ago quarter
Net cash
$-664.59M
Q3 FY2026
Operating margin
-39.4%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1576280
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $361.0M | $335.0M | $301.7M | $281.3M | $265.2M |
| Operating income | -$132.8M | -$129.1M | -$121.3M | -$120.8M | -$99.0M |
| Net income | -$124.4M | -$120.1M | -$112.1M | -$128.5M | -$92.7M |
| Diluted EPS | -$0.93 | -$0.90 | -$0.85 | -$1.00 | -$0.74 |
| Operating cash flow | -$23.7M | -$57.8M | -$65.6M | -$26.4M | -$35.4M |
| Free cash flow | -$37.2M | -$69.5M | -$71.2M | -$54.2M | -$45.8M |
| Total assets | $1.9B | $1.9B | $1.9B | $2.0B | $1.3B |
| Total liabilities | $2.2B | $2.1B | $2.1B | $2.1B | $1.6B |
| Stockholders' equity | -$275.9M | -$222.9M | -$181.1M | -$99.3M | -$354.5M |
| Cash and investments | $1.0B | $1.1B | $1.1B | $1.2B | $580.0M |
| Total debt | $1.7B | $1.7B | $1.7B | $1.7B | $1.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
All 1003 Guardant Health, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.